◆ TICKERBASE交互式视图 →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

首页全部股票 › PODD · English version

Insulet Corporation (PODD)

来自官方财务报表的收入、利润与现金流历史。

Health Care · 华尔街(美国) · 最近更新: 2026-09-19

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.

关键数据

查看交互式图表与完整报表 → 估值模型 (DCF) →

年度利润表

利润表TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
总收入$3.1B$2.7B$2.1B$1.7B$1.3B$1.1B$904M$738M$564M$464M$367M$264M$289M$247M$211M$152M$97M$66M$36M$13M$4M
毛利$2.2B$1.9B$1.4B$1.2B$806M$752M$582M$480M$370M$277M$211M$133M$143M$112M$92M$67M$44M$18M($5M)($12M)($12M)
毛利率%71.1%71.6%69.8%68.3%61.7%68.5%64.4%65.1%65.6%59.8%57.5%50.5%49.6%45.5%43.7%43.8%45.1%27.7%-12.7%-92.4%-327.5%
营业利润(EBIT)$516M$474M$309M$220M$38M$126M$52M$50M$27M($7M)($11M)($49M)($12M)($29M)($36M)($42M)($39M)($59M)($89M)($54M)($35M)
营业利润率%16.9%17.5%14.9%13.0%2.9%11.5%5.7%6.8%4.9%-1.6%-2.9%-18.5%-4.3%-11.8%-17.0%-27.9%-39.8%-89.9%-247.8%-402.7%-945.8%
净利$376M$247M$418M$206M$5M$17M$7M$12M$3M($27M)($29M)($74M)($52M)($45M)($52M)($57M)($61M)($80M)($93M)($54M)($36M)
净利润率 %12.3%9.1%20.2%12.2%0.4%1.5%0.8%1.6%0.6%-5.8%-7.9%-27.9%-17.8%-18.2%-24.5%-37.5%-63.1%-120.5%-257.3%-400.4%-981.4%
EBITDA$532M$424M$324M$109M$140M$110M$74M$43M$6M$1M($33M)$0M($17M)($25M)($28M)($33M)($54M)($75M)($49M)($32M)
每股收益(EPS)$5.35$3.44$5.66$2.80$0.07$0.24$0.10$0.19$0.05$-0.46$-0.50$-1.29$-0.93$-0.83$-1.08$-1.22$-1.54$-2.68$-3.36$-3.21$-39.19
已发行股数 (M)72M74M74M70M69M66M62M61M58M57M57M56M54M48M47M40M30M28M1M

来源:公司公开报告(SEC)。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 PODD 交互式查看器。 /companies/us/PODD

类似公司

本网站信息仅用于教育与参考,不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.